There was an increase of grade 3 or 4 rash and hypothyroidism in patients who received PD-1 inhibitors, possibly due to the addition of the PD-1 inhibitor, which was considered an immune-related AE and is consistent with the reports from other studies (33). The gene discussed is PDCD1; the disease is hypothyroidism.